Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $380.00 → $510.00 | Neutral → Buy | Redburn Atlantic |
| 7/10/2024 | $462.00 → $512.00 | Buy | Citigroup |
| 5/30/2024 | $500.00 | Buy | Goldman |
| 11/17/2023 | $318.00 | Buy | HSBC Securities |
| 7/19/2023 | $377.00 | Outperform | Robert W. Baird |
| 4/19/2023 | $240.00 → $270.00 | In-line | Evercore ISI |
| 4/19/2023 | $305.00 → $317.00 | Buy | Citigroup |
| 4/19/2023 | $284.00 → $313.00 | Buy | BTIG Research |
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
Redburn Atlantic upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $510.00 from $380.00 previously
Citigroup reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $512.00 from $462.00 previously
Goldman initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $500.00
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 5 years by 8.25% on an annualized basis producing an average annual return of 20.86%. Currently, Intuitive Surgical has a market capitalization of $161.64 billion. Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 5 years ago, it would be worth $2,588.58 today based on a price of $454.88 for ISRG at the time of writing. Intuitive Surgical's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's
Barclays analyst Matt Miksic maintains Intuitive Surgical (NASDAQ:ISRG) with a Overweight and raises the price target from $490 to $510.
Intuitive Surgical Inc. (NASDAQ:ISRG) stock is trading higher on Friday after the robotic-assisted surgery company reported second-quarter earnings that were better than expected. William Blair writes, “All this comes in spite of several headwinds—China macro/anticorruption efforts, South Korea physician strikes, worsening bariatric volumes, and a somewhat strained supply chain—emphasizing the underlying momentum of the business and pointing to upside potential as these headwinds stabilize/improve through 2024 and especially into 2025.” The analyst adds the momentum remains strong due to the support of general surgery in the U.S. and non-urology procedures internationally, as Intuitive
144 - INTUITIVE SURGICAL INC (0001035267) (Subject)
10-Q - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2024. Q3 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the third quarter of 2023.The Company placed 379 da Vinci surgical systems, compared with 312 in the third quarter of 2023. The third quarter 2024 da Vinci surgical system placements included 110 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,539 systems as of Septemb
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2024. Q3 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the third quarter of 2023.The Company placed 379 da Vinci surgical systems, compared with 312 in the third quarter of 2023. The third quarter 2024 da Vinci surgical system placements included 110 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,539 systems as of Septemb
SUNNYVALE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2024. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023.The Company placed 341 da Vinci surgical systems, compared with 331 in the second quarter of 2023. The second quarter 2024 da Vinci surgical system placements included 70 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,203 systems as of June 30, 2024, an increase of 14%
SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023.The Company placed 313 da Vinci surgical systems, compared with 312 in the first quarter of 2023.The Company grew its da Vinci surgical system installed base to 8,887 systems as of March 31, 2024, an increase of 14% compared with 7,779 as of the end of the first quarter of 2023.First quarter 2024 revenue of $1.89 billion
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit